Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Monday,Benzinga reports. They currently have a $320.00 target price on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. Sanford C. Bernstein dropped their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. TD Cowen upped their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. Raymond James boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Finally, Chardan Capital reissued a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $251.01 on Monday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The stock has a 50-day moving average of $248.15 and a two-hundred day moving average of $259.81. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a market cap of $32.38 billion, a P/E ratio of -95.81 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 EPS. As a group, research analysts predict that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Sara Bay Financial lifted its position in shares of Alnylam Pharmaceuticals by 31.3% during the 4th quarter. Sara Bay Financial now owns 985 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 235 shares during the last quarter. Merit Financial Group LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $587,000. Empirical Asset Management LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $12,145,000. Gateway Investment Advisers LLC grew its holdings in shares of Alnylam Pharmaceuticals by 19.8% in the 4th quarter. Gateway Investment Advisers LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $1,737,000 after buying an additional 1,222 shares during the period. Finally, Burney Co. lifted its position in Alnylam Pharmaceuticals by 22.9% in the 4th quarter. Burney Co. now owns 25,738 shares of the biopharmaceutical company’s stock valued at $6,056,000 after acquiring an additional 4,791 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.